#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Impaired	_
1-2	9-19	prefrontal	_
1-3	20-30	functional	_
1-4	31-43	connectivity	_
1-5	44-54	associated	_
1-6	55-59	with	_
1-7	60-67	working	_
1-8	68-74	memory	_
1-9	75-79	task	_
1-10	80-91	performance	_
1-11	92-95	and	_
1-12	96-111	disorganization	_
1-13	112-119	despite	_
1-14	120-126	intact	_
1-15	127-138	activations	_
1-16	139-141	in	_
1-17	142-155	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-18	156-157	.	_

2-1	158-165	Working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
2-2	166-172	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
2-3	173-174	(	_
2-4	175-177	WM	_
2-5	178-179	)	_
2-6	180-188	deficits	_
2-7	189-192	are	_
2-8	193-196	key	_
2-9	197-205	features	_
2-10	206-208	of	_
2-11	209-222	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-12	223-226	and	_
2-13	227-230	are	_
2-14	231-241	associated	_
2-15	242-246	with	_
2-16	247-258	significant	_
2-17	259-269	functional	_
2-18	270-280	impairment	_
2-19	281-282	.	_

3-1	283-286	The	_
3-2	287-294	precise	_
3-3	295-305	mechanisms	_
3-4	306-308	of	_
3-5	309-311	WM	_
3-6	312-315	and	_
3-7	316-321	their	_
3-8	322-334	relationship	_
3-9	335-342	between	_
3-10	343-345	WM	_
3-11	346-354	deficits	_
3-12	355-359	with	_
3-13	360-365	other	_
3-14	366-374	clinical	_
3-15	375-383	symptoms	_
3-16	384-386	of	_
3-17	387-400	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-18	401-407	remain	_
3-19	408-415	unclear	_
3-20	416-417	.	_

4-1	418-430	Contemporary	_
4-2	431-437	models	_
4-3	438-445	propose	_
4-4	446-450	that	_
4-5	451-453	WM	_
4-6	454-462	requires	_
4-7	463-474	synchronous	_
4-8	475-483	activity	_
4-9	484-490	across	_
4-10	491-496	brain	_
4-11	497-504	regions	_
4-12	505-511	within	_
4-13	512-513	a	_
4-14	514-525	distributed	_
4-15	526-533	network	_
4-16	534-535	,	_
4-17	536-545	including	_
4-18	546-553	lateral	_
4-19	554-564	prefrontal	_
4-20	565-571	cortex	_
4-21	572-573	(	_
4-22	574-577	PFC	_
4-23	578-579	)	_
4-24	580-583	and	_
4-25	584-597	task-relevant	_
4-26	598-607	posterior	_
4-27	608-615	sensory	_
4-28	616-624	cortical	_
4-29	625-632	regions	_
4-30	633-634	.	_

5-1	635-639	This	_
5-2	640-648	suggests	_
5-3	649-653	that	_
5-4	654-656	WM	_
5-5	657-665	deficits	_
5-6	666-668	in	_
5-7	669-677	patients	_
5-8	678-681	may	_
5-9	682-684	be	_
5-10	685-688	due	_
5-11	689-691	to	_
5-12	692-695	PFC	_
5-13	696-706	functional	_
5-14	707-719	connectivity	_
5-15	720-721	(	_
5-16	722-724	FC	_
5-17	725-726	)	_
5-18	727-738	impairments	_
5-19	739-745	rather	_
5-20	746-750	than	_
5-21	751-761	activation	_
5-22	762-773	impairments	_
5-23	774-777	per	_
5-24	778-780	se	_
5-25	781-782	.	_

6-1	783-785	We	_
6-2	786-792	tested	_
6-3	793-797	this	_
6-4	798-808	hypothesis	_
6-5	809-811	by	_
6-6	812-821	measuring	_
6-7	822-825	the	_
6-8	826-835	magnitude	_
6-9	836-838	of	_
6-10	839-841	FC	_
6-11	842-849	between	_
6-12	850-857	lateral	_
6-13	858-861	PFC	_
6-14	862-865	and	_
6-15	866-872	visual	_
6-16	873-879	cortex	_
6-17	880-883	and	_
6-18	884-894	univariate	_
6-19	895-906	activations	_
6-20	907-913	within	_
6-21	914-919	these	_
6-22	920-927	regions	_
6-23	928-934	during	_
6-24	935-941	visual	_
6-25	942-944	WM	_
6-26	945-946	.	_

7-1	947-949	We	_
7-2	950-955	found	_
7-3	956-965	decreased	_
7-4	966-968	FC	_
7-5	969-971	in	_
7-6	972-980	patients	_
7-7	981-989	compared	_
7-8	990-992	to	_
7-9	993-1000	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-10	1001-1009	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-11	1010-1012	in	_
7-12	1013-1016	the	_
7-13	1017-1024	context	_
7-14	1025-1027	of	_
7-15	1028-1035	similar	_
7-16	1036-1042	levels	_
7-17	1043-1045	of	_
7-18	1046-1056	univariate	_
7-19	1057-1065	activity	_
7-20	1066-1067	.	_

8-1	1068-1079	Furthermore	_
8-2	1080-1081	,	_
8-3	1082-1086	this	_
8-4	1087-1096	decreased	_
8-5	1097-1099	FC	_
8-6	1100-1103	was	_
8-7	1104-1114	associated	_
8-8	1115-1119	with	_
8-9	1120-1124	task	_
8-10	1125-1136	performance	_
8-11	1137-1140	and	_
8-12	1141-1149	clinical	_
8-13	1150-1164	symptomatology	_
8-14	1165-1167	in	_
8-15	1168-1176	patients	_
8-16	1177-1178	.	_

9-1	1179-1182	The	_
9-2	1183-1192	magnitude	_
9-3	1193-1195	of	_
9-4	1196-1198	FC	_
9-5	1199-1200	,	_
9-6	1201-1213	particularly	_
9-7	1214-1220	during	_
9-8	1221-1224	the	_
9-9	1225-1230	delay	_
9-10	1231-1237	period	_
9-11	1238-1239	,	_
9-12	1240-1243	was	_
9-13	1244-1254	positively	_
9-14	1255-1265	correlated	_
9-15	1266-1270	with	_
9-16	1271-1273	WM	_
9-17	1274-1278	task	_
9-18	1279-1287	accuracy	_
9-19	1288-1289	,	_
9-20	1290-1295	while	_
9-21	1296-1298	FC	_
9-22	1299-1305	during	_
9-23	1306-1309	cue	_
9-24	1310-1313	was	_
9-25	1314-1323	inversely	_
9-26	1324-1334	correlated	_
9-27	1335-1339	with	_
9-28	1340-1348	severity	_
9-29	1349-1351	of	_
9-30	1352-1367	disorganization	_
9-31	1368-1369	.	_

10-1	1370-1375	Taken	_
10-2	1376-1384	together	_
10-3	1385-1386	,	_
10-4	1387-1392	these	_
10-5	1393-1400	results	_
10-6	1401-1408	suggest	_
10-7	1409-1413	that	_
10-8	1414-1424	impairment	_
10-9	1425-1427	in	_
10-10	1428-1435	lateral	_
10-11	1436-1439	PFC	_
10-12	1440-1442	FC	_
10-13	1443-1445	is	_
10-14	1446-1447	a	_
10-15	1448-1451	key	_
10-16	1452-1458	aspect	_
10-17	1459-1461	of	_
10-18	1462-1473	information	_
10-19	1474-1484	processing	_
10-20	1485-1495	impairment	_
10-21	1496-1498	in	_
10-22	1499-1507	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-23	1508-1512	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-24	1513-1526	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-25	1527-1528	,	_
10-26	1529-1532	and	_
10-27	1533-1536	may	_
10-28	1537-1539	be	_
10-29	1540-1541	a	_
10-30	1542-1551	sensitive	_
10-31	1552-1557	index	_
10-32	1558-1560	of	_
10-33	1561-1568	altered	_
10-34	1569-1584	neurophysiology	_
10-35	1585-1586	.	_

11-1	1587-1594	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1595-1603	Subjects	_
11-3	1604-1606	18	_
11-4	1607-1615	patients	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-5	1616-1620	with	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-6	1621-1634	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-7	1635-1637	or	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-8	1638-1653	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-9	1654-1662	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-10	1663-1664	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-11	1665-1667	SZ	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-12	1668-1669	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
11-13	1670-1673	and	_
11-14	1674-1676	19	_
11-15	1677-1684	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-16	1685-1692	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-17	1693-1694	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-18	1695-1697	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-19	1698-1699	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-20	1700-1708	subjects	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
11-21	1709-1713	were	_
11-22	1714-1723	recruited	_
11-23	1724-1728	from	_
11-24	1729-1732	the	_
11-25	1733-1742	community	_
11-26	1743-1746	for	_
11-27	1747-1751	this	_
11-28	1752-1757	study	_
11-29	1758-1759	.	_

12-1	1760-1763	Two	_
12-2	1764-1766	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-3	1767-1770	and	_
12-4	1771-1774	one	_
12-5	1775-1777	HC	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
12-6	1778-1785	subject	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
12-7	1786-1790	were	_
12-8	1791-1799	excluded	_
12-9	1800-1803	due	_
12-10	1804-1806	to	_
12-11	1807-1816	excessive	_
12-12	1817-1825	movement	_
12-13	1826-1832	and/or	_
12-14	1833-1837	very	_
12-15	1838-1842	poor	_
12-16	1843-1854	performance	_
12-17	1855-1857	on	_
12-18	1858-1861	the	_
12-19	1862-1864	WM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
12-20	1865-1869	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
12-21	1870-1871	.	_

13-1	1872-1876	Data	_
13-2	1877-1881	from	_
13-3	1882-1884	16	_
13-4	1885-1887	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
13-5	1888-1891	and	_
13-6	1892-1894	18	_
13-7	1895-1897	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-8	1898-1906	subjects	_
13-9	1907-1911	were	_
13-10	1912-1916	used	_
13-11	1917-1920	for	_
13-12	1921-1928	further	_
13-13	1929-1937	analyses	_
13-14	1938-1939	(	_
13-15	1940-1945	Table	_
13-16	1946-1947	1	_
13-17	1948-1949	)	_
13-18	1950-1951	.	_

14-1	1952-1955	All	_
14-2	1956-1964	patients	_
14-3	1965-1969	were	_
14-4	1970-1980	clinically	_
14-5	1981-1987	stable	_
14-6	1988-1992	with	_
14-7	1993-2004	medications	_
14-8	2005-2009	that	_
14-9	2010-2014	were	_
14-10	2015-2024	unchanged	_
14-11	2025-2031	within	_
14-12	2032-2035	two	_
14-13	2036-2041	weeks	_
14-14	2042-2044	of	_
14-15	2045-2050	study	_
14-16	2051-2064	participation	_
14-17	2065-2066	.	_

15-1	2067-2073	Master	_
15-2	2074-2075	’	_
15-3	2076-2078	s-	_
15-4	2079-2082	and	_
15-5	2083-2097	doctoral-level	_
15-6	2098-2108	clinicians	_
15-7	2109-2118	evaluated	_
15-8	2119-2127	subjects	_
15-9	2128-2132	with	_
15-10	2133-2136	the	_
15-11	2137-2147	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-12	2148-2156	Clinical	_
15-13	2157-2166	Interview	_
15-14	2167-2170	for	_
15-15	2171-2181	Diagnostic	_
15-16	2182-2185	and	_
15-17	2186-2197	Statistical	_
15-18	2198-2204	Manual	_
15-19	2205-2207	of	_
15-20	2208-2214	Mental	_
15-21	2215-2224	Disorders	_
15-22	2225-2226	,	_
15-23	2227-2233	Fourth	_
15-24	2234-2241	Edition	_
15-25	2242-2243	,	_
15-26	2244-2248	Text	_
15-27	2249-2257	Revision	_
15-28	2258-2259	(	_
15-29	2260-2269	DSM-IV-TR	_
15-30	2270-2271	)	_
15-31	2272-2274	to	_
15-32	2275-2282	confirm	_
15-33	2283-2286	the	_
15-34	2287-2296	diagnoses	_
15-35	2297-2299	in	_
15-36	2300-2302	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-37	2303-2306	and	_
15-38	2307-2309	to	_
15-39	2310-2317	exclude	_
15-40	2318-2321	the	_
15-41	2322-2330	presence	_
15-42	2331-2333	of	_
15-43	2334-2335	a	_
15-44	2336-2341	major	_
15-45	2342-2353	psychiatric	_
15-46	2354-2361	illness	_
15-47	2362-2364	in	_
15-48	2365-2367	HC	_
15-49	2368-2369	.	_

16-1	2370-2373	All	_
16-2	2374-2382	patients	_
16-3	2383-2387	were	_
16-4	2388-2394	taking	_
16-5	2395-2409	antipsychotics	_
16-6	2410-2412	at	_
16-7	2413-2416	the	_
16-8	2417-2421	time	_
16-9	2422-2424	of	_
16-10	2425-2432	testing	_
16-11	2433-2434	.	_

17-1	2435-2444	Exclusion	_
17-2	2445-2453	criteria	_
17-3	2454-2457	for	_
17-4	2458-2460	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-5	2461-2465	were	_
17-6	2466-2467	1	_
17-7	2468-2469	)	_
17-8	2470-2478	presence	_
17-9	2479-2481	of	_
17-10	2482-2483	a	_
17-11	2484-2492	lifetime	_
17-12	2493-2502	diagnosis	_
17-13	2503-2505	of	_
17-14	2506-2508	an	_
17-15	2509-2513	axis	_
17-16	2514-2515	I	_
17-17	2516-2524	disorder	_
17-18	2525-2527	or	_
17-19	2528-2529	2	_
17-20	2530-2531	)	_
17-21	2532-2533	a	_
17-22	2534-2540	first-	_
17-23	2541-2547	degree	_
17-24	2548-2556	relative	_
17-25	2557-2561	with	_
17-26	2562-2563	a	_
17-27	2564-2573	psychotic	_
17-28	2574-2582	disorder	_
17-29	2583-2584	.	_

18-1	2585-2594	Exclusion	_
18-2	2595-2603	criteria	_
18-3	2604-2607	for	_
18-4	2608-2612	both	_
18-5	2613-2618	study	_
18-6	2619-2625	groups	_
18-7	2626-2630	were	_
18-8	2631-2632	:	_
18-9	2633-2634	1	_
18-10	2635-2636	)	_
18-11	2637-2639	IQ	_
18-12	2640-2641	<	_
18-13	2642-2644	70	_
18-14	2645-2646	,	_
18-15	2647-2648	2	_
18-16	2649-2650	)	_
18-17	2651-2658	history	_
18-18	2659-2661	of	_
18-19	2662-2666	drug	_
18-20	2667-2669	or	_
18-21	2670-2677	alcohol	_
18-22	2678-2688	dependence	_
18-23	2689-2691	or	_
18-24	2692-2697	abuse	_
18-25	2698-2704	within	_
18-26	2705-2710	three	_
18-27	2711-2717	months	_
18-28	2718-2720	of	_
18-29	2721-2726	study	_
18-30	2727-2729	or	_
18-31	2730-2731	a	_
18-32	2732-2740	positive	_
18-33	2741-2746	urine	_
18-34	2747-2751	drug	_
18-35	2752-2758	screen	_
18-36	2759-2761	on	_
18-37	2762-2765	day	_
18-38	2766-2768	of	_
18-39	2769-2774	study	_
18-40	2775-2776	,	_
18-41	2777-2778	3	_
18-42	2779-2780	)	_
18-43	2781-2792	significant	_
18-44	2793-2797	head	_
18-45	2798-2804	trauma	_
18-46	2805-2806	,	_
18-47	2807-2809	or	_
18-48	2810-2811	4	_
18-49	2812-2813	)	_
18-50	2814-2817	any	_
18-51	2818-2823	known	_
18-52	2824-2840	contraindication	_
18-53	2841-2843	to	_
18-54	2844-2847	MRI	_
18-55	2848-2849	.	_

19-1	2850-2855	After	_
19-2	2856-2864	complete	_
19-3	2865-2876	description	_
19-4	2877-2879	of	_
19-5	2880-2883	the	_
19-6	2884-2889	study	_
19-7	2890-2893	was	_
19-8	2894-2899	given	_
19-9	2900-2901	,	_
19-10	2902-2909	written	_
19-11	2910-2918	informed	_
19-12	2919-2926	consent	_
19-13	2927-2930	was	_
19-14	2931-2939	obtained	_
19-15	2940-2944	from	_
19-16	2945-2948	all	_
19-17	2949-2961	participants	_
19-18	2962-2963	.	_

20-1	2964-2967	The	_
20-2	2968-2973	study	_
20-3	2974-2977	was	_
20-4	2978-2986	approved	_
20-5	2987-2989	by	_
20-6	2990-2993	the	_
20-7	2994-3004	University	_
20-8	3005-3007	of	_
20-9	3008-3018	California	_
20-10	3019-3024	Davis	_
20-11	3025-3038	Institutional	_
20-12	3039-3045	Review	_
20-13	3046-3051	Board	_
20-14	3052-3053	.	_

21-1	3054-3063	Cognitive	_
21-2	3064-3072	Paradigm	_
21-3	3073-3081	Stimulus	_
21-4	3082-3094	presentation	_
21-5	3095-3098	and	_
21-6	3099-3107	response	_
21-7	3108-3118	recordings	_
21-8	3119-3123	were	_
21-9	3124-3133	conducted	_
21-10	3134-3138	with	_
21-11	3139-3146	E-Prime	_
21-12	3147-3148	(	_
21-13	3149-3159	Psychology	_
21-14	3160-3168	Software	_
21-15	3169-3174	Tools	_
21-16	3175-3176	,	_
21-17	3177-3181	Inc.	_
21-18	3182-3183	,	_
21-19	3184-3194	Pittsburgh	_
21-20	3195-3196	,	_
21-21	3197-3199	PA	_
21-22	3200-3201	;	_
21-23	3202-3206	http	_
21-24	3207-3208	:	_
21-25	3209-3225	//www.pstnet.com	_
21-26	3226-3227	)	_
21-27	3228-3229	.	_

22-1	3230-3237	Stimuli	_
22-2	3238-3242	were	_
22-3	3243-3252	projected	_
22-4	3253-3257	onto	_
22-5	3258-3259	a	_
22-6	3260-3266	screen	_
22-7	3267-3273	viewed	_
22-8	3274-3276	by	_
22-9	3277-3289	participants	_
22-10	3290-3297	through	_
22-11	3298-3299	a	_
22-12	3300-3306	mirror	_
22-13	3307-3314	mounted	_
22-14	3315-3317	on	_
22-15	3318-3321	the	_
22-16	3322-3326	head	_
22-17	3327-3331	coil	_
22-18	3332-3333	.	_

23-1	3334-3346	Participants	_
23-2	3347-3356	performed	_
23-3	3357-3360	the	_
23-4	3361-3370	cognitive	_
23-5	3371-3379	paradigm	_
23-6	3380-3389	displayed	_
23-7	3390-3392	in	_
23-8	3393-3399	Figure	_
23-9	3400-3401	1	_
23-10	3402-3403	.	_

24-1	3404-3406	We	_
24-2	3407-3415	designed	_
24-3	3416-3417	a	_
24-4	3418-3423	novel	_
24-5	3424-3430	visual	_
24-6	3431-3433	WM	_
24-7	3434-3442	paradigm	_
24-8	3443-3445	to	_
24-9	3446-3456	facilitate	_
24-10	3457-3460	the	_
24-11	3461-3468	planned	_
24-12	3469-3477	unbiased	_
24-13	3478-3479	,	_
24-14	3480-3490	functional	_
24-15	3491-3500	ROI-based	_
24-16	3501-3505	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
24-17	3506-3514	analyses	_
24-18	3515-3516	.	_

25-1	3517-3520	The	_
25-2	3521-3527	design	_
25-3	3528-3530	of	_
25-4	3531-3534	our	_
25-5	3535-3541	visual	_
25-6	3542-3548	object	_
25-7	3549-3551	WM	_
25-8	3552-3556	task	_
25-9	3557-3567	temporally	_
25-10	3568-3578	segregates	_
25-11	3579-3582	the	_
25-12	3583-3589	phases	_
25-13	3590-3592	of	_
25-14	3593-3596	cue	_
25-15	3597-3598	,	_
25-16	3599-3604	delay	_
25-17	3605-3606	,	_
25-18	3607-3610	and	_
25-19	3611-3616	probe	_
25-20	3617-3618	.	_

26-1	3619-3621	In	_
26-2	3622-3626	this	_
26-3	3627-3633	manner	_
26-4	3634-3635	,	_
26-5	3636-3640	this	_
26-6	3641-3645	task	_
26-7	3646-3649	can	_
26-8	3650-3652	be	_
26-9	3653-3663	considered	_
26-10	3664-3665	a	_
26-11	3666-3673	variant	_
26-12	3674-3676	of	_
26-13	3677-3680	the	_
26-14	3681-3690	Sternberg	_
26-15	3691-3695	Task	_
26-16	3696-3697	.	_

27-1	3698-3702	This	_
27-2	3703-3709	design	_
27-3	3710-3713	was	_
27-4	3714-3720	chosen	_
27-5	3721-3725	over	_
27-6	3726-3727	a	_
27-7	3728-3739	traditional	_
27-8	3740-3746	N-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-9	3747-3751	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-10	3752-3754	in	_
27-11	3755-3760	which	_
27-12	3761-3764	the	_
27-13	3765-3770	three	_
27-14	3771-3777	phases	_
27-15	3778-3781	can	_
27-16	3782-3785	not	_
27-17	3786-3788	be	_
27-18	3789-3799	temporally	_
27-19	3800-3809	separated	_
27-20	3810-3811	.	_

28-1	3812-3817	There	_
28-2	3818-3822	were	_
28-3	3823-3826	two	_
28-4	3827-3832	tasks	_
28-5	3833-3835	in	_
28-6	3836-3840	this	_
28-7	3841-3849	paradigm	_
28-8	3850-3851	,	_
28-9	3852-3857	which	_
28-10	3858-3862	were	_
28-11	3863-3872	identical	_
28-12	3873-3875	in	_
28-13	3876-3881	terms	_
28-14	3882-3884	of	_
28-15	3885-3890	trial	_
28-16	3891-3900	structure	_
28-17	3901-3902	,	_
28-18	3903-3911	stimulus	_
28-19	3912-3925	presentations	_
28-20	3926-3927	,	_
28-21	3928-3933	order	_
28-22	3934-3937	and	_
28-23	3938-3944	timing	_
28-24	3945-3946	,	_
28-25	3947-3950	but	_
28-26	3951-3959	differed	_
28-27	3960-3962	in	_
28-28	3963-3965	WM	_
28-29	3966-3978	requirements	_
28-30	3979-3980	.	_

29-1	3981-3984	The	_
29-2	3985-3990	first	_
29-3	3991-3999	stimulus	_
29-4	4000-4009	presented	_
29-5	4010-4012	in	_
29-6	4013-4017	both	_
29-7	4018-4023	tasks	_
29-8	4024-4026	is	_
29-9	4027-4035	referred	_
29-10	4036-4038	to	_
29-11	4039-4041	as	_
29-12	4042-4045	the	_
29-13	4046-4047	“	_
29-14	4048-4051	cue	_
29-15	4052-4053	”	_
29-16	4054-4058	face	_
29-17	4059-4060	.	_

30-1	4061-4063	It	_
30-2	4064-4067	was	_
30-3	4068-4077	displayed	_
30-4	4078-4081	for	_
30-5	4082-4085	one	_
30-6	4086-4092	second	_
30-7	4093-4096	and	_
30-8	4097-4101	then	_
30-9	4102-4104	it	_
30-10	4105-4108	was	_
30-11	4109-4117	replaced	_
30-12	4118-4120	by	_
30-13	4121-4122	a	_
30-14	4123-4132	crosshair	_
30-15	4133-4134	.	_

31-1	4135-4138	The	_
31-2	4139-4144	color	_
31-3	4145-4147	of	_
31-4	4148-4151	the	_
31-5	4152-4161	crosshair	_
31-6	4162-4165	was	_
31-7	4166-4175	initially	_
31-8	4176-4181	black	_
31-9	4182-4183	,	_
31-10	4184-4187	but	_
31-11	4188-4195	changed	_
31-12	4196-4201	color	_
31-13	4202-4207	after	_
31-14	4208-4211	two	_
31-15	4212-4219	seconds	_
31-16	4220-4221	.	_

32-1	4222-4226	This	_
32-2	4227-4230	new	_
32-3	4231-4236	color	_
32-4	4237-4246	indicated	_
32-5	4247-4250	the	_
32-6	4251-4255	task	_
32-7	4256-4258	of	_
32-8	4259-4262	the	_
32-9	4263-4268	trial	_
32-10	4269-4270	:	_
32-11	4271-4275	blue	_
32-12	4276-4285	indicated	_
32-13	4286-4289	the	_
32-14	4290-4292	WM	_
32-15	4293-4297	task	_
32-16	4298-4299	,	_
32-17	4300-4305	which	_
32-18	4306-4314	required	_
32-19	4315-4323	subjects	_
32-20	4324-4326	to	_
32-21	4327-4335	maintain	_
32-22	4336-4339	the	_
32-23	4340-4343	cue	_
32-24	4344-4348	face	_
32-25	4349-4351	in	_
32-26	4352-4354	WM	_
32-27	4355-4361	across	_
32-28	4362-4363	a	_
32-29	4364-4366	15	_
32-30	4367-4368	s	_
32-31	4369-4374	delay	_
32-32	4375-4381	period	_
32-33	4382-4385	and	_
32-34	4386-4388	to	_
32-35	4389-4393	make	_
32-36	4394-4395	a	_
32-37	4396-4401	match	_
32-38	4402-4416	discrimination	_
32-39	4417-4421	with	_
32-40	4422-4425	the	_
32-41	4426-4430	face	_
32-42	4431-4440	appearing	_
32-43	4441-4443	at	_
32-44	4444-4447	the	_
32-45	4448-4451	end	_
32-46	4452-4454	of	_
32-47	4455-4458	the	_
32-48	4459-4464	delay	_
32-49	4465-4466	;	_
32-50	4467-4470	red	_
32-51	4471-4480	indicated	_
32-52	4481-4484	the	_
32-53	4485-4491	Gender	_
32-54	4492-4494	ID	_
32-55	4495-4496	(	_
32-56	4497-4500	GID	_
32-57	4501-4502	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
32-58	4503-4507	task	_
32-59	4508-4509	,	_
32-60	4510-4515	which	_
32-61	4516-4519	did	_
32-62	4520-4523	not	_
32-63	4524-4531	require	_
32-64	4532-4534	WM	_
32-65	4535-4538	for	_
32-66	4539-4543	task	_
32-67	4544-4554	completion	_
32-68	4555-4558	but	_
32-69	4559-4565	rather	_
32-70	4566-4569	for	_
32-71	4570-4573	the	_
32-72	4574-4582	subjects	_
32-73	4583-4585	to	_
32-74	4586-4590	make	_
32-75	4591-4592	a	_
32-76	4593-4599	gender	_
32-77	4600-4614	discrimination	_
32-78	4615-4617	of	_
32-79	4618-4621	the	_
32-80	4622-4626	face	_
32-81	4627-4636	appearing	_
32-82	4637-4639	at	_
32-83	4640-4643	the	_
32-84	4644-4647	end	_
32-85	4648-4650	of	_
32-86	4651-4654	the	_
32-87	4655-4660	delay	_
32-88	4661-4667	period	_
32-89	4668-4669	.	_

33-1	4670-4673	The	_
33-2	4674-4679	faces	_
33-3	4680-4685	shown	_
33-4	4686-4690	were	_
33-5	4691-4697	chosen	_
33-6	4698-4700	to	_
33-7	4701-4703	be	_
33-8	4704-4710	gender	_
33-9	4711-4720	ambiguous	_
33-10	4721-4722	,	_
33-11	4723-4725	so	_
33-12	4726-4729	the	_
33-13	4730-4737	results	_
33-14	4738-4742	from	_
33-15	4743-4746	the	_
33-16	4747-4750	GID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
33-17	4751-4755	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
33-18	4756-4759	are	_
33-19	4760-4763	not	_
33-20	4764-4772	expected	_
33-21	4773-4775	to	_
33-22	4776-4778	be	_
33-23	4779-4789	meaningful	_
33-24	4790-4791	.	_

34-1	4792-4793	A	_
34-2	4794-4802	critical	_
34-3	4803-4809	aspect	_
34-4	4810-4812	of	_
34-5	4813-4816	the	_
34-6	4817-4823	design	_
34-7	4824-4827	was	_
34-8	4828-4832	that	_
34-9	4833-4836	the	_
34-10	4837-4841	task	_
34-11	4842-4845	for	_
34-12	4846-4847	a	_
34-13	4848-4858	particular	_
34-14	4859-4864	trial	_
34-15	4865-4868	was	_
34-16	4869-4877	revealed	_
34-17	4878-4882	only	_
34-18	4883-4888	after	_
34-19	4889-4892	cue	_
34-20	4893-4897	face	_
34-21	4898-4904	offset	_
34-22	4905-4906	.	_

35-1	4907-4911	This	_
35-2	4912-4918	design	_
35-3	4919-4925	forced	_
35-4	4926-4934	subjects	_
35-5	4935-4937	to	_
35-6	4938-4944	encode	_
35-7	4945-4949	into	_
35-8	4950-4952	WM	_
35-9	4953-4954	a	_
35-10	4955-4958	cue	_
35-11	4959-4963	face	_
35-12	4964-4972	whenever	_
35-13	4973-4975	it	_
35-14	4976-4984	appeared	_
35-15	4985-4986	,	_
35-16	4987-4991	even	_
35-17	4992-4998	during	_
35-18	4999-5002	GID	_
35-19	5003-5009	trials	_
35-20	5010-5011	.	_

36-1	5012-5023	Furthermore	_
36-2	5024-5025	,	_
36-3	5026-5029	the	_
36-4	5030-5035	trial	_
36-5	5036-5040	task	_
36-6	5041-5044	was	_
36-7	5045-5053	revealed	_
36-8	5054-5057	two	_
36-9	5058-5065	seconds	_
36-10	5066-5067	,	_
36-11	5068-5071	and	_
36-12	5072-5075	not	_
36-13	5076-5087	immediately	_
36-14	5088-5089	,	_
36-15	5090-5095	after	_
36-16	5096-5099	cue	_
36-17	5100-5106	offset	_
36-18	5107-5109	in	_
36-19	5110-5115	order	_
36-20	5116-5118	to	_
36-21	5119-5126	enhance	_
36-22	5127-5130	the	_
36-23	5131-5139	temporal	_
36-24	5140-5150	separation	_
36-25	5151-5158	between	_
36-26	5159-5162	the	_
36-27	5163-5173	engagement	_
36-28	5174-5176	of	_
36-29	5177-5185	encoding	_
36-30	5186-5189	and	_
36-31	5190-5201	maintenance	_
36-32	5202-5209	related	_
36-33	5210-5216	neural	_
36-34	5217-5226	processes	_
36-35	5227-5229	by	_
36-36	5230-5233	the	_
36-37	5234-5241	subject	_
36-38	5242-5243	.	_

37-1	5244-5248	This	_
37-2	5249-5257	temporal	_
37-3	5258-5268	separation	_
37-4	5269-5271	is	_
37-5	5272-5281	necessary	_
37-6	5282-5284	to	_
37-7	5285-5297	disambiguate	_
37-8	5298-5301	the	_
37-9	5302-5306	BOLD	_
37-10	5307-5313	signal	_
37-11	5314-5324	reflecting	_
37-12	5325-5333	encoding	_
37-13	5334-5337	and	_
37-14	5338-5349	maintenance	_
37-15	5350-5357	related	_
37-16	5358-5364	events	_
37-17	5365-5366	.	_

38-1	5367-5375	Subjects	_
38-2	5376-5385	completed	_
38-3	5386-5388	40	_
38-4	5389-5395	trials	_
38-5	5396-5398	of	_
38-6	5399-5403	each	_
38-7	5404-5408	task	_
38-8	5409-5410	.	_

39-1	5411-5416	There	_
39-2	5417-5421	were	_
39-3	5422-5425	ten	_
39-4	5426-5432	trials	_
39-5	5433-5439	within	_
39-6	5440-5444	each	_
39-7	5445-5447	of	_
39-8	5448-5453	eight	_
39-9	5454-5458	runs	_
39-10	5459-5460	.	_

40-1	5461-5466	Trial	_
40-2	5467-5472	order	_
40-3	5473-5476	was	_
40-4	5477-5485	randomly	_
40-5	5486-5496	intermixed	_
40-6	5497-5498	.	_

41-1	5499-5501	To	_
41-2	5502-5508	ensure	_
41-3	5509-5513	that	_
41-4	5514-5517	all	_
41-5	5518-5526	subjects	_
41-6	5527-5531	were	_
41-7	5532-5539	engaged	_
41-8	5540-5544	with	_
41-9	5545-5548	the	_
41-10	5549-5553	task	_
41-11	5554-5555	,	_
41-12	5556-5558	we	_
41-13	5559-5566	imposed	_
41-14	5567-5568	a	_
41-15	5569-5580	performance	_
41-16	5581-5590	criterion	_
41-17	5591-5593	of	_
41-18	5594-5596	60	_
41-19	5597-5598	%	_
41-20	5599-5607	accuracy	_
41-21	5608-5610	on	_
41-22	5611-5614	the	_
41-23	5615-5617	WM	_
41-24	5618-5622	task	_
41-25	5623-5624	.	_

42-1	5625-5627	We	_
42-2	5628-5633	chose	_
42-3	5634-5635	a	_
42-4	5636-5638	WM	_
42-5	5639-5643	task	_
42-6	5644-5648	that	_
42-7	5649-5652	was	_
42-8	5653-5656	not	_
42-9	5657-5660	too	_
42-10	5661-5670	difficult	_
42-11	5671-5674	for	_
42-12	5675-5679	both	_
42-13	5680-5687	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
42-14	5688-5695	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
42-15	5696-5697	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
42-16	5698-5700	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
42-17	5701-5702	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
42-18	5703-5706	and	_
42-19	5707-5720	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
42-20	5721-5722	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
42-21	5723-5725	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
42-22	5726-5727	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
42-23	5728-5734	groups	_
42-24	5735-5737	to	_
42-25	5738-5748	accurately	_
42-26	5749-5757	complete	_
42-27	5758-5760	so	_
42-28	5761-5765	that	_
42-29	5766-5771	there	_
42-30	5772-5777	would	_
42-31	5778-5780	be	_
42-32	5781-5791	sufficient	_
42-33	5792-5798	number	_
42-34	5799-5801	of	_
42-35	5802-5809	correct	_
42-36	5810-5816	trials	_
42-37	5817-5821	with	_
42-38	5822-5827	which	_
42-39	5828-5830	to	_
42-40	5831-5838	conduct	_
42-41	5839-5842	the	_
42-42	5843-5845	FC	_
42-43	5846-5854	analyses	_
42-44	5855-5856	.	_

43-1	5857-5858	A	_
43-2	5859-5863	task	_
43-3	5864-5868	that	_
43-4	5869-5872	was	_
43-5	5873-5876	too	_
43-6	5877-5886	difficult	_
43-7	5887-5892	would	_
43-8	5893-5899	likely	_
43-9	5900-5904	have	_
43-10	5905-5912	yielded	_
43-11	5913-5914	a	_
43-12	5915-5921	fairly	_
43-13	5922-5927	large	_
43-14	5928-5938	difference	_
43-15	5939-5945	across	_
43-16	5946-5952	groups	_
43-17	5953-5955	in	_
43-18	5956-5959	the	_
43-19	5960-5966	number	_
43-20	5967-5969	of	_
43-21	5970-5977	correct	_
43-22	5978-5984	trials	_
43-23	5985-5986	.	_

44-1	5987-5990	Low	_
44-2	5991-5998	correct	_
44-3	5999-6004	trial	_
44-4	6005-6012	numbers	_
44-5	6013-6015	in	_
44-6	6016-6019	the	_
44-7	6020-6027	patient	_
44-8	6028-6033	group	_
44-9	6034-6039	would	_
44-10	6040-6046	reduce	_
44-11	6047-6050	our	_
44-12	6051-6058	ability	_
44-13	6059-6061	to	_
44-14	6062-6070	reliably	_
44-15	6071-6078	measure	_
44-16	6079-6083	true	_
44-17	6084-6086	FC	_
44-18	6087-6095	strength	_
44-19	6096-6099	and	_
44-20	6100-6101	a	_
44-21	6102-6107	large	_
44-22	6108-6113	group	_
44-23	6114-6124	difference	_
44-24	6125-6127	in	_
44-25	6128-6133	trial	_
44-26	6134-6141	numbers	_
44-27	6142-6147	could	_
44-28	6148-6157	introduce	_
44-29	6158-6162	bias	_
44-30	6163-6165	in	_
44-31	6166-6171	terms	_
44-32	6172-6174	of	_
44-33	6175-6180	group	_
44-34	6181-6192	comparisons	_
44-35	6193-6194	.	_

45-1	6195-6200	Using	_
45-2	6201-6205	this	_
45-3	6206-6214	approach	_
45-4	6215-6216	,	_
45-5	6217-6219	we	_
45-6	6220-6230	identified	_
45-7	6231-6235	task	_
45-8	6236-6244	relevant	_
45-9	6245-6255	functional	_
45-10	6256-6260	ROIs	_
45-11	6261-6263	in	_
45-12	6264-6267	the	_
45-13	6268-6275	lateral	_
45-14	6276-6279	PFC	_
45-15	6280-6283	and	_
45-16	6284-6290	visual	_
45-17	6291-6297	cortex	_
45-18	6298-6301	and	_
45-19	6302-6309	derived	_
45-20	6310-6319	estimates	_
45-21	6320-6322	of	_
45-22	6323-6326	the	_
45-23	6327-6335	strength	_
45-24	6336-6338	of	_
45-25	6339-6349	PFC-visual	_
45-26	6350-6356	cortex	_
45-27	6357-6359	FC	_
45-28	6360-6362	to	_
45-29	6363-6367	test	_
45-30	6368-6371	the	_
45-31	6372-6382	hypothesis	_
45-32	6383-6385	of	_
45-33	6386-6389	PFC	_
45-34	6390-6392	FC	_
45-35	6393-6404	impairments	_
45-36	6405-6408	and	_
45-37	6409-6414	their	_
45-38	6415-6427	associations	_
45-39	6428-6432	with	_
45-40	6433-6437	task	_
45-41	6438-6449	performance	_
45-42	6450-6453	and	_
45-43	6454-6468	symptomatology	_
45-44	6469-6471	in	_
45-45	6472-6485	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
45-46	6486-6487	.	_

46-1	6488-6492	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-2	6493-6504	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-3	6505-6508	and	_
46-4	6509-6519	processing	_
46-5	6520-6524	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-6	6525-6530	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
46-7	6531-6535	were	_
46-8	6536-6545	completed	_
46-9	6546-6548	on	_
46-10	6549-6550	a	_
46-11	6551-6558	Siemens	_
46-12	6559-6561	3T	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
46-13	6562-6566	TRIO	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
46-14	6567-6569	MR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
46-15	6570-6576	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
46-16	6577-6581	with	_
46-17	6582-6584	an	_
46-18	6585-6590	eight	_
46-19	6591-6598	channel	_
46-20	6599-6605	phased	_
46-21	6606-6611	array	_
46-22	6612-6616	head	_
46-23	6617-6621	coil	_
46-24	6622-6623	.	_

47-1	6624-6628	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-2	6629-6636	volumes	_
47-3	6637-6641	were	_
47-4	6642-6650	acquired	_
47-5	6651-6656	using	_
47-6	6657-6660	the	_
47-7	6661-6670	following	_
47-8	6671-6681	parameters	_
47-9	6682-6683	:	_
47-10	6684-6686	36	_
47-11	6687-6693	3.5-mm	_
47-12	6694-6701	oblique	_
47-13	6702-6707	axial	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-14	6708-6710	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-15	6711-6712	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-16	6713-6722	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-17	6723-6736	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-18	6737-6740	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
47-19	6741-6747	slices	_
47-20	6748-6749	,	_
47-21	6750-6754	with	_
47-22	6755-6759	2000	_
47-23	6760-6762	ms	_
47-24	6763-6765	TR	_
47-25	6766-6767	,	_
47-26	6768-6770	28	_
47-27	6771-6773	ms	_
47-28	6774-6776	TE	_
47-29	6777-6778	,	_
47-30	6779-6781	60	_
47-31	6782-6788	degree	_
47-32	6789-6793	flip	_
47-33	6794-6799	angle	_
47-34	6800-6803	and	_
47-35	6804-6807	240	_
47-36	6808-6810	mm	_
47-37	6811-6812	×	_
47-38	6813-6816	240	_
47-39	6817-6819	mm	_
47-40	6820-6825	field	_
47-41	6826-6828	of	_
47-42	6829-6833	view	_
47-43	6834-6836	in	_
47-44	6837-6838	a	_
47-45	6839-6841	64	_
47-46	6842-6843	×	_
47-47	6844-6846	64	_
47-48	6847-6853	matrix	_
47-49	6854-6855	.	_

48-1	6856-6860	Each	_
48-2	6861-6871	functional	_
48-3	6872-6875	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-4	6876-6879	was	_
48-5	6880-6888	preceded	_
48-6	6889-6891	by	_
48-7	6892-6896	five	_
48-8	6897-6903	images	_
48-9	6904-6906	of	_
48-10	6907-6917	unanalyzed	_
48-11	6918-6922	data	_
48-12	6923-6925	to	_
48-13	6926-6931	allow	_
48-14	6932-6944	steady-state	_
48-15	6945-6958	magnetization	_
48-16	6959-6961	to	_
48-17	6962-6964	be	_
48-18	6965-6973	achieved	_
48-19	6974-6975	.	_

49-1	6976-6989	Preprocessing	_
49-2	6990-6992	of	_
49-3	6993-6997	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-4	6998-7005	volumes	_
49-5	7006-7010	with	_
49-6	7011-7014	the	_
49-7	7015-7026	Statistical	_
49-8	7027-7037	Parametric	_
49-9	7038-7045	Mapping	_
49-10	7046-7047	,	_
49-11	7048-7055	version	_
49-12	7056-7057	8	_
49-13	7058-7059	(	_
49-14	7060-7064	SPM8	_
49-15	7065-7066	)	_
49-16	7067-7075	software	_
49-17	7076-7083	package	_
49-18	7084-7092	included	_
49-19	7093-7101	temporal	_
49-20	7102-7105	and	_
49-21	7106-7113	spatial	_
49-22	7114-7125	realignment	_
49-23	7126-7127	,	_
49-24	7128-7141	normalization	_
49-25	7142-7144	to	_
49-26	7145-7148	the	_
49-27	7149-7152	EPI	_
49-28	7153-7161	template	_
49-29	7162-7163	,	_
49-30	7164-7168	.001	_
49-31	7169-7171	Hz	_
49-32	7172-7181	high-pass	_
49-33	7182-7191	filtering	_
49-34	7192-7195	and	_
49-35	7196-7203	spatial	_
49-36	7204-7213	smoothing	_
49-37	7214-7218	with	_
49-38	7219-7220	8	_
49-39	7221-7223	mm	_
49-40	7224-7228	FWHM	_
49-41	7229-7237	Gaussian	_
49-42	7238-7244	kernel	_
49-43	7245-7246	.	_

50-1	7247-7249	We	_
50-2	7250-7258	excluded	_
50-3	7259-7262	two	_
50-4	7263-7265	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-5	7266-7269	and	_
50-6	7270-7273	one	_
50-7	7274-7276	HC	_
50-8	7277-7284	subject	_
50-9	7285-7288	for	_
50-10	7289-7299	exhibiting	_
50-11	7300-7307	greater	_
50-12	7308-7312	than	_
50-13	7313-7314	4	_
50-14	7315-7317	mm	_
50-15	7318-7328	within-run	_
50-16	7329-7337	movement	_
50-17	7338-7339	.	_

51-1	7340-7344	This	_
51-2	7345-7354	threshold	_
51-3	7355-7358	was	_
51-4	7359-7365	chosen	_
51-5	7366-7368	as	_
51-6	7369-7372	the	_
51-7	7373-7377	size	_
51-8	7378-7380	of	_
51-9	7381-7382	a	_
51-10	7383-7388	voxel	_
51-11	7389-7392	was	_
51-12	7393-7394	4	_
51-13	7395-7397	mm	_
51-14	7398-7400	in	_
51-15	7401-7406	plane	_
51-16	7407-7408	.	_

52-1	7409-7410	A	_
52-2	7411-7421	comparison	_
52-3	7422-7424	of	_
52-4	7425-7429	mean	_
52-5	7430-7439	framewise	_
52-6	7440-7452	displacement	_
52-7	7453-7455	of	_
52-8	7456-7464	included	_
52-9	7465-7473	subjects	_
52-10	7474-7480	during	_
52-11	7481-7489	scanning	_
52-12	7490-7499	indicated	_
52-13	7500-7507	absence	_
52-14	7508-7510	of	_
52-15	7511-7522	significant	_
52-16	7523-7536	between-group	_
52-17	7537-7547	difference	_
52-18	7548-7550	in	_
52-19	7551-7555	this	_
52-20	7556-7564	variable	_
52-21	7565-7566	(	_
52-22	7567-7574	p=0.292	_
52-23	7575-7576	)	_
52-24	7577-7578	.	_

53-1	7579-7581	In	_
53-2	7582-7590	addition	_
53-3	7591-7592	,	_
53-4	7593-7595	we	_
53-5	7596-7600	also	_
53-6	7601-7606	found	_
53-7	7607-7609	no	_
53-8	7610-7615	group	_
53-9	7616-7626	difference	_
53-10	7627-7629	in	_
53-11	7630-7633	the	_
53-12	7634-7648	frame-by-frame	_
53-13	7649-7656	changes	_
53-14	7657-7659	in	_
53-15	7660-7663	any	_
53-16	7664-7666	of	_
53-17	7667-7670	the	_
53-18	7671-7674	six	_
53-19	7675-7683	movement	_
53-20	7684-7694	parameters	_
53-21	7695-7696	,	_
53-22	7697-7698	p	_
53-23	7699-7700	>	_
53-24	7701-7705	0.13	_
53-25	7706-7707	.	_

54-1	7708-7710	We	_
54-2	7711-7715	also	_
54-3	7716-7725	conducted	_
54-4	7726-7736	additional	_
54-5	7737-7745	post-hoc	_
54-6	7746-7754	analyses	_
54-7	7755-7756	,	_
54-8	7757-7766	described	_
54-9	7767-7772	below	_
54-10	7773-7774	,	_
54-11	7775-7777	to	_
54-12	7778-7782	rule	_
54-13	7783-7786	out	_
54-14	7787-7790	the	_
54-15	7791-7802	possibility	_
54-16	7803-7805	of	_
54-17	7806-7810	head	_
54-18	7811-7819	movement	_
54-19	7820-7831	confounding	_
54-20	7832-7835	our	_
54-21	7836-7843	results	_
54-22	7844-7845	.	_

55-1	7846-7850	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-2	7851-7859	analysis	_
55-3	7860-7864	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-4	7865-7873	modeling	_
55-5	7874-7878	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-6	7879-7883	data	_
55-7	7884-7892	modeling	_
55-8	7893-7902	proceeded	_
55-9	7903-7908	under	_
55-10	7909-7910	a	_
55-11	7911-7915	slow	_
55-12	7916-7929	event-related	_
55-13	7930-7936	design	_
55-14	7937-7946	framework	_
55-15	7947-7948	,	_
55-16	7949-7953	with	_
55-17	7954-7957	the	_
55-18	7958-7967	canonical	_
55-19	7968-7983	double-gaussian	_
55-20	7984-7995	hemodynamic	_
55-21	7996-8004	response	_
55-22	8005-8013	function	_
55-23	8014-8023	convolved	_
55-24	8024-8028	with	_
55-25	8029-8039	regressors	_
55-26	8040-8043	for	_
55-27	8044-8046	WM	_
55-28	8047-8055	encoding	_
55-29	8056-8057	,	_
55-30	8058-8069	maintenance	_
55-31	8070-8073	and	_
55-32	8074-8082	response	_
55-33	8083-8084	,	_
55-34	8085-8098	corresponding	_
55-35	8099-8101	to	_
55-36	8102-8105	cue	_
55-37	8106-8107	,	_
55-38	8108-8113	delay	_
55-39	8114-8117	and	_
55-40	8118-8123	probe	_
55-41	8124-8130	events	_
55-42	8131-8132	.	_

56-1	8133-8136	The	_
56-2	8137-8142	three	_
56-3	8143-8147	task	_
56-4	8148-8154	phases	_
56-5	8155-8159	were	_
56-6	8160-8167	modeled	_
56-7	8168-8170	in	_
56-8	8171-8174	the	_
56-9	8175-8184	following	_
56-10	8185-8191	manner	_
56-11	8192-8193	:	_
56-12	8194-8204	encoding—a	_
56-13	8205-8211	single	_
56-14	8212-8221	covariate	_
56-15	8222-8228	during	_
56-16	8229-8232	cue	_
56-17	8233-8245	presentation	_
56-18	8246-8248	at	_
56-19	8249-8252	the	_
56-20	8253-8262	beginning	_
56-21	8263-8265	of	_
56-22	8266-8269	the	_
56-23	8270-8275	trial	_
56-24	8276-8277	(	_
56-25	8278-8281	t=0	_
56-26	8282-8283	s	_
56-27	8284-8285	)	_
56-28	8286-8287	;	_
56-29	8288-8301	maintenance—a	_
56-30	8302-8308	single	_
56-31	8309-8318	covariate	_
56-32	8319-8321	in	_
56-33	8322-8325	the	_
56-34	8326-8332	middle	_
56-35	8333-8335	of	_
56-36	8336-8339	the	_
56-37	8340-8345	delay	_
56-38	8346-8352	period	_
56-39	8353-8354	(	_
56-40	8355-8358	t=7	_
56-41	8359-8360	s	_
56-42	8361-8362	)	_
56-43	8363-8366	and	_
56-44	8367-8377	response—a	_
56-45	8378-8384	single	_
56-46	8385-8394	covariate	_
56-47	8395-8401	during	_
56-48	8402-8407	probe	_
56-49	8408-8420	presentation	_
56-50	8421-8422	(	_
56-51	8423-8427	t=16	_
56-52	8428-8429	s	_
56-53	8430-8431	)	_
56-54	8432-8433	.	_

57-1	8434-8436	We	_
57-2	8437-8445	included	_
57-3	8446-8449	the	_
57-4	8450-8455	first	_
57-5	8456-8464	temporal	_
57-6	8465-8475	derivative	_
57-7	8476-8478	of	_
57-8	8479-8489	covariates	_
57-9	8490-8492	in	_
57-10	8493-8496	the	_
57-11	8497-8507	regression	_
57-12	8508-8514	matrix	_
57-13	8515-8517	to	_
57-14	8518-8525	account	_
57-15	8526-8529	for	_
57-16	8530-8539	potential	_
57-17	8540-8545	group	_
57-18	8546-8557	differences	_
57-19	8558-8560	in	_
57-20	8561-8565	BOLD	_
57-21	8566-8572	signal	_
57-22	8573-8581	temporal	_
57-23	8582-8590	dynamics	_
57-24	8591-8600	resulting	_
57-25	8601-8605	from	_
57-26	8606-8617	differences	_
57-27	8618-8620	in	_
57-28	8621-8629	response	_
57-29	8630-8635	times	_
57-30	8636-8638	or	_
57-31	8639-8644	other	_
57-32	8645-8654	variables	_
57-33	8655-8656	.	_

58-1	8657-8659	We	_
58-2	8660-8664	also	_
58-3	8665-8673	included	_
58-4	8674-8677	the	_
58-5	8678-8681	six	_
58-6	8682-8690	movement	_
58-7	8691-8701	parameters	_
58-8	8702-8704	in	_
58-9	8705-8708	our	_
58-10	8709-8715	models	_
58-11	8716-8717	.	_

59-1	8718-8723	There	_
59-2	8724-8728	were	_
59-3	8729-8737	separate	_
59-4	8738-8748	covariates	_
59-5	8749-8752	for	_
59-6	8753-8760	correct	_
59-7	8761-8764	and	_
59-8	8765-8774	incorrect	_
59-9	8775-8781	trials	_
59-10	8782-8783	,	_
59-11	8784-8787	but	_
59-12	8788-8792	only	_
59-13	8793-8800	correct	_
59-14	8801-8807	trials	_
59-15	8808-8812	were	_
59-16	8813-8821	analyzed	_
59-17	8822-8829	because	_
59-18	8830-8833	the	_
59-19	8834-8840	number	_
59-20	8841-8843	of	_
59-21	8844-8853	incorrect	_
59-22	8854-8860	trials	_
59-23	8861-8864	was	_
59-24	8865-8868	too	_
59-25	8869-8874	small	_
59-26	8875-8877	to	_
59-27	8878-8885	produce	_
59-28	8886-8896	meaningful	_
59-29	8897-8904	results	_
59-30	8905-8906	.	_

60-1	8907-8909	We	_
60-2	8910-8918	included	_
60-3	8919-8921	an	_
60-4	8922-8931	analogous	_
60-5	8932-8935	set	_
60-6	8936-8938	of	_
60-7	8939-8949	covariates	_
60-8	8950-8953	for	_
60-9	8954-8957	the	_
60-10	8958-8961	GID	_
60-11	8962-8968	trials	_
60-12	8969-8970	.	_

61-1	8971-8983	Localization	_
61-2	8984-8986	of	_
61-3	8987-8997	functional	_
61-4	8998-9002	ROIs	_
61-5	9003-9008	Given	_
61-6	9009-9012	the	_
61-7	9013-9021	abundant	_
61-8	9022-9031	empirical	_
61-9	9032-9036	data	_
61-10	9037-9048	implicating	_
61-11	9049-9052	the	_
61-12	9053-9061	specific	_
61-13	9062-9067	brain	_
61-14	9068-9075	regions	_
61-15	9076-9084	involved	_
61-16	9085-9087	in	_
61-17	9088-9094	visual	_
61-18	9095-9097	WM	_
61-19	9098-9101	and	_
61-20	9102-9105	the	_
61-21	9106-9118	connectivity	_
61-22	9119-9124	model	_
61-23	9125-9127	of	_
61-24	9128-9130	WM	_
61-25	9131-9135	with	_
61-26	9136-9141	these	_
61-27	9142-9146	ROIs	_
61-28	9147-9148	,	_
61-29	9149-9151	we	_
61-30	9152-9155	did	_
61-31	9156-9159	not	_
61-32	9160-9166	employ	_
61-33	9167-9168	a	_
61-34	9169-9174	whole	_
61-35	9175-9180	brain	_
61-36	9181-9182	,	_
61-37	9183-9193	voxel-wise	_
61-38	9194-9202	analysis	_
61-39	9203-9206	and	_
61-40	9207-9214	instead	_
61-41	9215-9217	we	_
61-42	9218-9226	utilized	_
61-43	9227-9229	an	_
61-44	9230-9233	ROI	_
61-45	9234-9239	based	_
61-46	9240-9248	approach	_
61-47	9249-9252	for	_
61-48	9253-9263	hypothesis	_
61-49	9264-9271	testing	_
61-50	9272-9273	.	_

62-1	9274-9278	This	_
62-2	9279-9289	approached	_
62-3	9290-9298	required	_
62-4	9299-9309	specifying	_
62-5	9310-9311	a	_
62-6	9312-9318	priori	_
62-7	9319-9322	the	_
62-8	9323-9327	ROIs	_
62-9	9328-9330	to	_
62-10	9331-9333	be	_
62-11	9334-9342	analyzed	_
62-12	9343-9344	(	_
62-13	9345-9352	lateral	_
62-14	9353-9356	PFC	_
62-15	9357-9360	and	_
62-16	9361-9368	ventral	_
62-17	9369-9375	visual	_
62-18	9376-9382	cortex	_
62-19	9383-9384	)	_
62-20	9385-9386	.	_

63-1	9387-9389	We	_
63-2	9390-9398	utilized	_
63-3	9399-9409	functional	_
63-4	9410-9414	ROIs	_
63-5	9415-9416	,	_
63-6	9417-9423	rather	_
63-7	9424-9428	than	_
63-8	9429-9437	anatomic	_
63-9	9438-9442	ROIs	_
63-10	9443-9444	,	_
63-11	9445-9448	for	_
63-12	9449-9459	hypothesis	_
63-13	9460-9467	testing	_
63-14	9468-9470	to	_
63-15	9471-9478	enhance	_
63-16	9479-9490	sensitivity	_
63-17	9491-9493	to	_
63-18	9494-9500	detect	_
63-19	9501-9505	true	_
63-20	9506-9513	effects	_
63-21	9514-9515	.	_

64-1	9516-9519	The	_
64-2	9520-9527	lateral	_
64-3	9528-9531	PFC	_
64-4	9532-9534	is	_
64-5	9535-9536	a	_
64-6	9537-9547	relatively	_
64-7	9548-9553	broad	_
64-8	9554-9560	region	_
64-9	9561-9565	that	_
64-10	9566-9577	encompasses	_
64-11	9578-9590	functionally	_
64-12	9591-9604	heterogeneous	_
64-13	9605-9616	sub-regions	_
64-14	9617-9618	.	_

65-1	9619-9623	Thus	_
65-2	9624-9625	,	_
65-3	9626-9629	the	_
65-4	9630-9633	use	_
65-5	9634-9636	of	_
65-6	9637-9649	anatomically	_
65-7	9650-9657	defined	_
65-8	9658-9662	ROIs	_
65-9	9663-9665	of	_
65-10	9666-9669	the	_
65-11	9670-9677	lateral	_
65-12	9678-9681	PFC	_
65-13	9682-9687	would	_
65-14	9688-9694	likely	_
65-15	9695-9708	significantly	_
65-16	9709-9717	diminish	_
65-17	9718-9721	our	_
65-18	9722-9729	ability	_
65-19	9730-9732	to	_
65-20	9733-9739	detect	_
65-21	9740-9751	WM-specific	_
65-22	9752-9756	fMRI	_
65-23	9757-9763	signal	_
65-24	9764-9765	.	_

66-1	9766-9769	One	_
66-2	9770-9772	of	_
66-3	9773-9776	the	_
66-4	9777-9782	major	_
66-5	9783-9793	challenges	_
66-6	9794-9796	in	_
66-7	9797-9807	functional	_
66-8	9808-9820	localization	_
66-9	9821-9823	is	_
66-10	9824-9827	the	_
66-11	9828-9829	“	_
66-12	9830-9835	curse	_
66-13	9836-9838	of	_
66-14	9839-9850	circularity	_
66-15	9851-9852	”	_
66-16	9853-9854	.	_

67-1	9855-9859	This	_
67-2	9860-9867	problem	_
67-3	9868-9874	arises	_
67-4	9875-9879	when	_
67-5	9880-9884	fMRI	_
67-6	9885-9889	data	_
67-7	9890-9894	that	_
67-8	9895-9897	is	_
67-9	9898-9901	not	_
67-10	9902-9913	independent	_
67-11	9914-9918	from	_
67-12	9919-9922	the	_
67-13	9923-9927	fMRI	_
67-14	9928-9932	data	_
67-15	9933-9935	to	_
67-16	9936-9938	be	_
67-17	9939-9947	analyzed	_
67-18	9948-9950	is	_
67-19	9951-9955	used	_
67-20	9956-9958	to	_
67-21	9959-9967	identify	_
67-22	9968-9970	or	_
67-23	9971-9977	define	_
67-24	9978-9982	ROIs	_
67-25	9983-9987	used	_
67-26	9988-9990	in	_
67-27	9991-9994	the	_
67-28	9995-10003	analysis	_
67-29	10004-10005	.	_

68-1	10006-10008	We	_
68-2	10009-10016	avoided	_
68-3	10017-10021	this	_
68-4	10022-10029	problem	_
68-5	10030-10032	by	_
68-6	10033-10038	using	_
68-7	10039-10044	scans	_
68-8	10045-10056	independent	_
68-9	10057-10059	of	_
68-10	10060-10062	WM	_
68-11	10063-10068	scans	_
68-12	10069-10070	,	_
68-13	10071-10074	e.g	_
68-14	10075-10076	.	_

69-1	10077-10080	GID	_
69-2	10081-10086	scans	_
69-3	10087-10088	,	_
69-4	10089-10091	to	_
69-5	10092-10100	localize	_
69-6	10101-10105	ROIs	_
69-7	10106-10109	and	_
69-8	10110-10114	used	_
69-9	10115-10120	these	_
69-10	10121-10125	ROIs	_
69-11	10126-10128	to	_
69-12	10129-10140	interrogate	_
69-13	10141-10143	WM	_
69-14	10144-10149	scans	_
69-15	10150-10151	.	_

70-1	10152-10154	We	_
70-2	10155-10160	first	_
70-3	10161-10170	generated	_
70-4	10171-10183	within-group	_
70-5	10184-10194	activation	_
70-6	10195-10199	maps	_
70-7	10200-10201	(	_
70-8	10202-10205	one	_
70-9	10206-10209	map	_
70-10	10210-10213	for	_
70-11	10214-10216	HC	_
70-12	10217-10220	and	_
70-13	10221-10224	one	_
70-14	10225-10228	map	_
70-15	10229-10232	for	_
70-16	10233-10235	SZ	_
70-17	10236-10237	)	_
70-18	10238-10239	(	_
70-19	10240-10246	Figure	_
70-20	10247-10248	2	_
70-21	10249-10250	)	_
70-22	10251-10256	which	_
70-23	10257-10261	were	_
70-24	10262-10269	defined	_
70-25	10270-10272	by	_
70-26	10273-10276	the	_
70-27	10277-10285	contrast	_
70-28	10286-10288	of	_
70-29	10289-10292	GID	_
70-30	10293-10296	cue	_
70-31	10297-10300	vs.	_
70-32	10301-10309	implicit	_
70-33	10310-10318	baseline	_
70-34	10319-10320	.	_

71-1	10321-10326	These	_
71-2	10327-10331	were	_
71-3	10332-10342	restricted	_
71-4	10343-10348	using	_
71-5	10349-10357	anatomic	_
71-6	10358-10363	masks	_
71-7	10364-10368	from	_
71-8	10369-10373	Wake	_
71-9	10374-10380	Forest	_
71-10	10381-10391	University	_
71-11	10392-10401	Pickatlas	_
71-12	10402-10403	(	_
71-13	10404-10408	http	_
71-14	10409-10410	:	_
71-15	10411-10432	//www.fmri.wfubmc.edu	_
71-16	10433-10434	)	_
71-17	10435-10436	.	_

72-1	10437-10440	The	_
72-2	10441-10446	union	_
72-3	10447-10449	of	_
72-4	10450-10453	the	_
72-5	10454-10462	superior	_
72-6	10463-10466	and	_
72-7	10467-10473	middle	_
72-8	10474-10482	inferior	_
72-9	10483-10487	gyri	_
72-10	10488-10491	and	_
72-11	10492-10495	the	_
72-12	10496-10501	union	_
72-13	10502-10504	of	_
72-14	10505-10513	fusiform	_
72-15	10514-10517	and	_
72-16	10518-10525	lingual	_
72-17	10526-10530	gyri	_
72-18	10531-10537	served	_
72-19	10538-10540	as	_
72-20	10541-10550	inclusive	_
72-21	10551-10556	masks	_
72-22	10557-10560	for	_
72-23	10561-10564	the	_
72-24	10565-10572	lateral	_
72-25	10573-10576	PFC	_
72-26	10577-10580	and	_
72-27	10581-10588	ventral	_
72-28	10589-10595	visual	_
72-29	10596-10602	cortex	_
72-30	10603-10604	,	_
72-31	10605-10617	respectively	_
72-32	10618-10619	.	_

73-1	10620-10623	The	_
73-2	10624-10628	size	_
73-3	10629-10631	of	_
73-4	10632-10635	the	_
73-5	10636-10646	functional	_
73-6	10647-10651	ROIs	_
73-7	10652-10655	was	_
73-8	10656-10666	determined	_
73-9	10667-10669	by	_
73-10	10670-10673	the	_
73-11	10674-10683	inclusion	_
73-12	10684-10686	of	_
73-13	10687-10690	all	_
73-14	10691-10697	voxels	_
73-15	10698-10707	surviving	_
73-16	10708-10709	a	_
73-17	10710-10720	voxel-wise	_
73-18	10721-10724	FDR	_
73-19	10725-10734	threshold	_
73-20	10735-10737	of	_
73-21	10738-10744	p=0.05	_
73-22	10745-10749	were	_
73-23	10750-10758	included	_
73-24	10759-10761	in	_
73-25	10762-10765	the	_
73-26	10766-10776	functional	_
73-27	10777-10781	ROIs	_
73-28	10782-10783	.	_

74-1	10784-10789	There	_
74-2	10790-10794	were	_
74-3	10795-10798	two	_
74-4	10799-10803	sets	_
74-5	10804-10806	of	_
74-6	10807-10810	PFC	_
74-7	10811-10814	and	_
74-8	10815-10821	visual	_
74-9	10822-10828	cortex	_
74-10	10829-10833	ROIs	_
74-11	10834-10835	,	_
74-12	10836-10839	one	_
74-13	10840-10843	set	_
74-14	10844-10847	for	_
74-15	10848-10850	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
74-16	10851-10852	,	_
74-17	10853-10856	and	_
74-18	10857-10864	another	_
74-19	10865-10868	set	_
74-20	10869-10872	for	_
74-21	10873-10875	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
74-22	10876-10877	.	_

75-1	10878-10881	For	_
75-2	10882-10893	exploratory	_
75-3	10894-10902	analyses	_
75-4	10903-10904	,	_
75-5	10905-10907	we	_
75-6	10908-10915	created	_
75-7	10916-10920	left	_
75-8	10921-10924	and	_
75-9	10925-10930	right	_
75-10	10931-10935	ROIs	_
75-11	10936-10939	for	_
75-12	10940-10943	the	_
75-13	10944-10947	PFC	_
75-14	10948-10951	and	_
75-15	10952-10958	visual	_
75-16	10959-10965	cortex	_
75-17	10966-10968	in	_
75-18	10969-10972	the	_
75-19	10973-10977	same	_
75-20	10978-10984	manner	_
75-21	10985-10994	described	_
75-22	10995-11000	above	_
75-23	11001-11002	,	_
75-24	11003-11007	with	_
75-25	11008-11011	the	_
75-26	11012-11017	added	_
75-27	11018-11028	constraint	_
75-28	11029-11031	of	_
75-29	11032-11042	hemisphere	_
75-30	11043-11044	.	_

76-1	11045-11055	Univariate	_
76-2	11056-11064	analysis	_
76-3	11065-11067	We	_
76-4	11068-11077	completed	_
76-5	11078-11081	two	_
76-6	11082-11087	types	_
76-7	11088-11090	of	_
76-8	11091-11101	univariate	_
76-9	11102-11111	analyses–	_
76-10	11112-11115	ROI	_
76-11	11116-11119	and	_
76-12	11120-11130	voxel-wise	_
76-13	11131-11136	whole	_
76-14	11137-11142	brain	_
76-15	11143-11144	.	_

77-1	11145-11148	The	_
77-2	11149-11155	former	_
77-3	11156-11159	was	_
77-4	11160-11169	conducted	_
77-5	11170-11172	so	_
77-6	11173-11177	that	_
77-7	11178-11180	we	_
77-8	11181-11186	could	_
77-9	11187-11195	directly	_
77-10	11196-11203	compare	_
77-11	11204-11214	univariate	_
77-12	11215-11218	and	_
77-13	11219-11221	FC	_
77-14	11222-11225	ROI	_
77-15	11226-11230	data	_
77-16	11231-11232	.	_

78-1	11233-11235	We	_
78-2	11236-11244	obtained	_
78-3	11245-11254	spatially	_
78-4	11255-11263	averaged	_
78-5	11264-11268	beta	_
78-6	11269-11278	estimates	_
78-7	11279-11283	from	_
78-8	11284-11294	univariate	_
78-9	11295-11299	fMRI	_
78-10	11300-11305	model	_
78-11	11306-11316	estimation	_
78-12	11317-11326	described	_
78-13	11327-11332	above	_
78-14	11333-11334	.	_

79-1	11335-11337	We	_
79-2	11338-11342	also	_
79-3	11343-11352	conducted	_
79-4	11353-11363	voxel-wise	_
79-5	11364-11369	whole	_
79-6	11370-11375	brain	_
79-7	11376-11389	between-group	_
79-8	11390-11398	analyses	_
79-9	11399-11401	to	_
79-10	11402-11409	explore	_
79-11	11410-11412	if	_
79-12	11413-11420	regions	_
79-13	11421-11427	beyond	_
79-14	11428-11431	the	_
79-15	11432-11442	functional	_
79-16	11443-11447	ROIs	_
79-17	11448-11457	exhibited	_
79-18	11458-11468	activation	_
79-19	11469-11480	differences	_
79-20	11481-11482	.	_

80-1	11483-11486	For	_
80-2	11487-11492	these	_
80-3	11493-11501	analyses	_
80-4	11502-11503	,	_
80-5	11504-11506	we	_
80-6	11507-11519	deliberately	_
80-7	11520-11525	chose	_
80-8	11526-11527	a	_
80-9	11528-11535	liberal	_
80-10	11536-11545	threshold	_
80-11	11546-11548	of	_
80-12	11549-11550	p	_
80-13	11551-11552	<	_
80-14	11553-11557	0.01	_
80-15	11558-11559	,	_
80-16	11560-11571	uncorrected	_
80-17	11572-11573	,	_
80-18	11574-11576	in	_
80-19	11577-11582	order	_
80-20	11583-11585	to	_
80-21	11586-11594	maximize	_
80-22	11595-11598	the	_
80-23	11599-11606	chances	_
80-24	11607-11609	of	_
80-25	11610-11617	finding	_
80-26	11618-11621	any	_
80-27	11622-11627	group	_
80-28	11628-11639	differences	_
80-29	11640-11641	.	_

81-1	11642-11644	We	_
81-2	11645-11649	also	_
81-3	11650-11659	conducted	_
81-4	11660-11666	within	_
81-5	11667-11672	group	_
81-6	11673-11683	voxel-wise	_
81-7	11684-11689	whole	_
81-8	11690-11695	brain	_
81-9	11696-11704	analyses	_
81-10	11705-11707	to	_
81-11	11708-11715	examine	_
81-12	11716-11719	the	_
81-13	11720-11725	level	_
81-14	11726-11728	of	_
81-15	11729-11740	activations	_
81-16	11741-11743	in	_
81-17	11744-11748	each	_
81-18	11749-11754	group	_
81-19	11755-11756	.	_

82-1	11757-11760	For	_
82-2	11761-11766	these	_
82-3	11767-11775	analyses	_
82-4	11776-11777	,	_
82-5	11778-11780	we	_
82-6	11781-11789	employed	_
82-7	11790-11802	conservative	_
82-8	11803-11812	corrected	_
82-9	11813-11820	methods	_
82-10	11821-11824	for	_
82-11	11825-11836	determining	_
82-12	11837-11847	activation	_
82-13	11848-11860	significance	_
82-14	11861-11862	,	_
82-15	11863-11864	a	_
82-16	11865-11881	cluster-defining	_
82-17	11882-11891	threshold	_
82-18	11892-11894	of	_
82-19	11895-11902	p=0.001	_
82-20	11903-11906	and	_
82-21	11907-11910	FDR	_
82-22	11911-11918	cluster	_
82-23	11919-11928	corrected	_
82-24	11929-11930	p	_
82-25	11931-11932	<	_
82-26	11933-11937	0.05	_
82-27	11938-11939	.	_

83-1	11940-11950	Functional	_
83-2	11951-11963	connectivity	_
83-3	11964-11967	The	_
83-4	11968-11979	beta-series	_
83-5	11980-11991	correlation	_
83-6	11992-11998	method	_
83-7	11999-12009	quantified	_
83-8	12010-12014	task	_
83-9	12015-12029	phase-specific	_
83-10	12030-12032	FC	_
83-11	12033-12040	between	_
83-12	12041-12046	brain	_
83-13	12047-12054	regions	_
83-14	12055-12056	.	_

84-1	12057-12061	This	_
84-2	12062-12068	method	_
84-3	12069-12076	employs	_
84-4	12077-12083	unique	_
84-5	12084-12094	covariates	_
84-6	12095-12098	for	_
84-7	12099-12104	every	_
84-8	12105-12110	trial	_
84-9	12111-12114	and	_
84-10	12115-12119	task	_
84-11	12120-12125	epoch	_
84-12	12126-12128	to	_
84-13	12129-12137	generate	_
84-14	12138-12143	trial	_
84-15	12144-12147	and	_
84-16	12148-12152	task	_
84-17	12153-12158	epoch	_
84-18	12159-12167	specific	_
84-19	12168-12177	estimates	_
84-20	12178-12180	of	_
84-21	12181-12189	activity	_
84-22	12190-12193	for	_
84-23	12194-12198	each	_
84-24	12199-12204	voxel	_
84-25	12205-12211	within	_
84-26	12212-12215	the	_
84-27	12216-12221	brain	_
84-28	12222-12223	(	_
84-29	12224-12228	beta	_
84-30	12229-12235	series	_
84-31	12236-12237	)	_
84-32	12238-12239	.	_

85-1	12240-12244	Beta	_
85-2	12245-12251	series	_
85-3	12252-12254	of	_
85-4	12255-12261	voxels	_
85-5	12262-12268	within	_
85-6	12269-12273	ROIs	_
85-7	12274-12275	(	_
85-8	12276-12279	PFC	_
85-9	12280-12283	and	_
85-10	12284-12290	visual	_
85-11	12291-12297	cortex	_
85-12	12298-12299	)	_
85-13	12300-12304	were	_
85-14	12305-12314	spatially	_
85-15	12315-12323	averaged	_
85-16	12324-12326	to	_
85-17	12327-12335	generate	_
85-18	12336-12339	PFC	_
85-19	12340-12343	and	_
85-20	12344-12350	visual	_
85-21	12351-12357	cortex	_
85-22	12358-12362	beta	_
85-23	12363-12369	series	_
85-24	12370-12371	,	_
85-25	12372-12377	which	_
85-26	12378-12382	were	_
85-27	12383-12387	then	_
85-28	12388-12398	correlated	_
85-29	12399-12403	with	_
85-30	12404-12408	each	_
85-31	12409-12414	other	_
85-32	12415-12417	to	_
85-33	12418-12426	quantify	_
85-34	12427-12435	strength	_
85-35	12436-12438	of	_
85-36	12439-12449	PFC-visual	_
85-37	12450-12456	cortex	_
85-38	12457-12459	FC	_
85-39	12460-12461	.	_

86-1	12462-12474	Correlations	_
86-2	12475-12478	The	_
86-3	12479-12486	Pearson	_
86-4	12487-12488	’	_
86-5	12489-12490	s	_
86-6	12491-12492	r	_
86-7	12493-12496	was	_
86-8	12497-12507	calculated	_
86-9	12508-12511	for	_
86-10	12512-12515	all	_
86-11	12516-12529	correlational	_
86-12	12530-12538	analyses	_
86-13	12539-12540	.	_

87-1	12541-12546	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-2	12547-12558	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-3	12559-12565	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-4	12566-12571	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-5	12572-12573	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-6	12574-12578	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-7	12579-12580	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
87-8	12581-12582	,	_
87-9	12583-12588	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-10	12589-12592	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-11	12593-12596	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-12	12597-12607	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-13	12608-12610	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-14	12611-12619	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-15	12620-12628	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-16	12629-12630	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-17	12631-12635	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-18	12636-12637	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
87-19	12638-12639	,	_
87-20	12640-12645	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-21	12646-12649	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-22	12650-12653	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-23	12654-12664	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-24	12665-12667	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-25	12668-12676	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-26	12677-12685	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-27	12686-12687	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-28	12688-12692	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-29	12693-12694	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
87-30	12695-12696	,	_
87-31	12697-12700	and	_
87-32	12701-12707	Global	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-33	12708-12718	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-34	12719-12724	Scale	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-35	12725-12726	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-36	12727-12730	GAS	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-37	12731-12732	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalStateAssessmentScale
87-38	12733-12743	quantified	_
87-39	12744-12752	symptoms	_
87-40	12753-12755	in	_
87-41	12756-12764	patients	_
87-42	12765-12766	,	_
87-43	12767-12770	and	_
87-44	12771-12775	were	_
87-45	12776-12780	used	_
87-46	12781-12784	for	_
87-47	12785-12796	exploratory	_
87-48	12797-12805	analyses	_
87-49	12806-12807	.	_

88-1	12808-12815	Pearson	_
88-2	12816-12817	’	_
88-3	12818-12819	s	_
88-4	12820-12821	r	_
88-5	12822-12825	was	_
88-6	12826-12836	calculated	_
88-7	12837-12839	to	_
88-8	12840-12847	examine	_
88-9	12848-12853	their	_
88-10	12854-12865	association	_
88-11	12866-12870	with	_
88-12	12871-12872	a	_
88-13	12873-12880	measure	_
88-14	12881-12883	of	_
88-15	12884-12886	FC	_
88-16	12887-12888	.	_

89-1	12889-12898	Magnitude	_
89-2	12899-12901	of	_
89-3	12902-12917	disorganization	_
89-4	12918-12919	(	_
89-5	12920-12928	distinct	_
89-6	12929-12933	from	_
89-7	12934-12943	psychotic	_
89-8	12944-12946	or	_
89-9	12947-12955	negative	_
89-10	12956-12964	symptoms	_
89-11	12965-12966	)	_
89-12	12967-12970	was	_
89-13	12971-12981	quantified	_
89-14	12982-12984	by	_
89-15	12985-12994	combining	_
89-16	12995-13004	component	_
89-17	13005-13009	item	_
89-18	13010-13016	scores	_
89-19	13017-13023	listed	_
89-20	13024-13029	below	_
89-21	13030-13034	from	_
89-22	13035-13040	these	_
89-23	13041-13047	scales	_
89-24	13048-13050	as	_
89-25	13051-13060	described	_
89-26	13061-13070	elsewhere	_
89-27	13071-13072	:	_
89-28	13073-13077	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
89-29	13078-13079	–	_
89-30	13080-13090	conceptual	_
89-31	13091-13106	disorganization	_
89-32	13107-13108	,	_
89-33	13109-13118	mannerism	_
89-34	13119-13122	and	_
89-35	13123-13132	posturing	_
89-36	13133-13134	,	_
89-37	13135-13138	and	_
89-38	13139-13153	disorientation	_
89-39	13154-13155	;	_
89-40	13156-13160	SANS	_
89-41	13161-13162	–	_
89-42	13163-13169	global	_
89-43	13170-13179	attention	_
89-44	13180-13181	;	_
89-45	13182-13186	SAPS	_
89-46	13187-13188	-	_
89-47	13189-13195	global	_
89-48	13196-13202	formal	_
89-49	13203-13210	thought	_
89-50	13211-13219	disorder	_
89-51	13220-13223	and	_
89-52	13224-13230	global	_
89-53	13231-13238	bizarre	_
89-54	13239-13247	behavior	_
89-55	13248-13250	..	_
89-56	13251-13258	Pearson	_
89-57	13259-13260	’	_
89-58	13261-13262	s	_
89-59	13263-13264	r	_
89-60	13265-13268	was	_
89-61	13269-13279	calculated	_
89-62	13280-13282	to	_
89-63	13283-13287	test	_
89-64	13288-13291	for	_
89-65	13292-13294	an	_
89-66	13295-13306	association	_
89-67	13307-13314	between	_
89-68	13315-13330	disorganization	_
89-69	13331-13334	and	_
89-70	13335-13337	FC	_
89-71	13338-13339	.	_

